Sotera Health (SHC) Q2 FY26 earnings call

Sotera Health reported a strong second quarter, driven by broad-based growth across all segments, particularly Sterigenics and Nordion. The company raised its full-year 2026 outlook for both revenue and adjusted EBITDA, reflecting confidence in its business model and execution. Management is focused on accelerating growth through internal investments, strategic M&A, and enhancing cross-business unit collaboration to better serve customers.